• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Axsome Therapeutics Inc.

    8/5/24 4:36:25 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    S-8 1 axsm-20240805.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 5, 2024

    Registration No. 333-

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    AXSOME THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

     

    45-4241907

    (State or other jurisdiction

     

    (IRS Employer Identification No.)

    of incorporation or organization)

     

     

     

    One World Trade Center

    22nd Floor

    New York, New York 10007

    (Address of principal executive offices) (Zip Code)

     

    Axsome Therapeutics, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan

    (Full title of the Plans)

     

    Herriot Tabuteau, M.D.
    President and Chief Executive Officer
    Axsome Therapeutics, Inc.
    One World Trade Center
    22nd Floor

    New York, New York 10007

    (Name and address of agent for service)

    (212) 332-3241

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

     

    Emilio Ragosa

    DLA Piper LLP (US)

    51 John F. Kennedy Parkway, Suite 120

    Short Hills, New Jersey 07078

    Telephone: (973) 520-2550

          Hunter Murdock

        General Counsel

                        Axsome Therapeutics, Inc.

                     One World Trade Center

                                            22nd Floor

                 New York, NY 10007

                          Telephone: (212) 332-3241

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

    Large accelerated filer ☒

     

    Accelerated filer ☐

    Non-accelerated filer ☐

     

    Smaller reporting company ☐

     

     

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    PART II

     

    Information Required in the Registration Statement

     

    This Registration Statement relates to the registration of an additional 1,894,054 shares (the “Shares”) of the common stock, par value $0.0001 per share, of Axsome Therapeutics, Inc. (the “Registrant”). The Shares are securities of the same class and relate to the same employee benefit plan, the 2015 Omnibus Incentive Compensation Plan, as those registered pursuant to the Registrant’s registration statements on Form S-8, previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 16, 2015, March 29, 2017, August 13, 2018, March 15, 2019, May 11, 2020, May 11, 2021, May 2, 2022, and May 9, 2023. In accordance with General Instruction E of Form S-8, the contents of the Registrant’s registration statements on Form S-8 (File Nos. 333-208579, 333-217002, 333-226824, 333-230296, 333-238174, 333-256019, 333-264621, and 333-271741) filed with the SEC on December 16, 2015, March 29, 2017, August 13, 2018, March 15, 2019, May 11, 2020, May 11, 2021, May 2, 2022, and May 9, 2023 are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

     

    Item 8. Exhibits

    Exhibit
    Number

     

    Exhibit

     

     

     

    5.1*

     

    Opinion and Consent of DLA Piper LLP (US).

     

     

     

    23.1*

     

    Consent of DLA Piper LLP (US) is contained in Exhibit 5.1.

     

     

     

    23.2*

     

    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.

     

     

     

    23.3*

     

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

     

     

     

    24.1*

     

    Power of Attorney. Reference is made to page 3 of this Registration Statement.

     

     

     

    99.1

     

    Axsome Therapeutics, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 10.2 to Registrant’s Annual Report on Form 10-K, filed on February 23, 2024).

     

     

     

    99.2

     

    Axsome Therapeutics, Inc. Form of Stock Option Agreement pursuant to the Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 99.2 to Registrant’s Registration Statement on Form S-8, File No. 333-208579, filed December 16, 2015).

     

     

     

    99.3

     

    Axsome Therapeutics, Inc. Form of Restricted Stock Unit Agreement (Non-Executives) pursuant to the Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 99.3 to the Company’s Registration Statement on Form S-8 (File No. 333-238174), filed May 11, 2020).

     

     

     

    99.4

     

    Axsome Therapeutics, Inc. Form of Restricted Stock Unit Agreement (Executives and Non-Employee Directors) pursuant to the Amended and Restated 2015 Omnibus Incentive Compensation Plan (Incorporated by reference, Exhibit 99.4 to the Company’s Registration Statement on Form S-8 (File No. 333-238174), filed May 11, 2020).

     

     

     

    107*

     

    Filing Fee Table.

    * Filed herewith

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on this 5th day of August, 2024.

     

    AXSOME THERAPEUTICS, INC.

     

     

     

     

    By

    /s/ Herriot Tabuteau, M.D.

     

     

    Herriot Tabuteau, M.D.

     

     

    Chief Executive Officer

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS:

    That each person whose signature appears below constitutes and appoints Herriot Tabuteau, M.D., Chief Executive Officer, and Nick Pizzie, Chief Financial Officer, and each of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes, may lawfully do or cause to be done by virtue thereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Herriot Tabuteau, M.D.

     

    Chief Executive Officer and Chairman of the Board (Principal Executive Officer)

     

    August 5, 2024

    Herriot Tabuteau, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Nick Pizzie, CPA, M.B.A.

     

    Chief Financial Officer (Principal Financial and Accounting Officer)

     

    August 5, 2024

    Nick Pizzie, CPA, M.B.A.

     

     

     

     

     

     

    /s/ Mark Coleman, M.D.

     

    Director

     

    August 5, 2024

    Mark Coleman, M.D.

     

     

     

     

     

     

     

     

     

     

    /s/ Roger Jeffs, Ph.D.

     

    Director

     

    August 5, 2024

    Roger Jeffs, Ph.D.

     

     

     

     

     

     

     

     

     

     

    /s/ Susan Mahony, Ph.D., M.B.A.

     

    Director

     

    August 5, 2024

    Susan Mahony, Ph.D., M.B.A.

     

     

     

     

     

     

    /s/ Mark Saad

     

    Director

     

    August 5, 2024

    Mark Saad

     

     

     

     

     


    Get the next $AXSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    1/8/2026$204.00Overweight → Equal-Weight
    Morgan Stanley
    10/1/2025$179.00Buy
    B. Riley Securities
    9/3/2025$163.00Overweight
    Wells Fargo
    7/3/2025$190.00Overweight
    Morgan Stanley
    6/3/2025$185.00Outperform
    Oppenheimer
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    More analyst ratings

    $AXSM
    SEC Filings

    View All

    SEC Form 144 filed by Axsome Therapeutics Inc.

    144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/2/26 5:30:05 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

    1/12/26 7:09:28 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Axsome Therapeutics Inc.

    144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

    1/7/26 4:44:23 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Axsome Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Axsome Therapeutics from Overweight to Equal-Weight and set a new price target of $204.00

    1/8/26 8:36:26 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Axsome Therapeutics with a new price target

    B. Riley Securities initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $179.00

    10/1/25 8:44:08 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Axsome Therapeutics with a new price target

    Wells Fargo resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $163.00

    9/3/25 8:28:49 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Coleman Mark bought $200,466 worth of shares (1,575 units at $127.28), increasing direct ownership by 3% to 48,212 units (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    9/9/25 8:11:58 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcas

    1/27/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

    NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia. FORWARD (Fibromyalgia Response with Esreboxetine Evaluated Using a Randomized Withdrawal Research Design) is a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial in patients with fibromyalgia consisting of an open-label AXS-14 treatment period and a randomized, double-blind treatment period. Patients achieving a treatment response d

    1/15/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

    Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively  AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI® preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively SYMBRAVO® preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, to

    1/12/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Coleman Mark exercised 5,193 shares at a strike of $8.02, increasing direct ownership by 11% to 53,405 units (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    2/10/26 7:11:27 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Tabuteau Herriot exercised 32,410 shares at a strike of $8.02 and sold $6,015,296 worth of shares (32,410 units at $185.60) (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    2/2/26 6:30:04 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Pizzie Nick exercised 12,000 shares at a strike of $3.50 and sold $2,255,040 worth of shares (12,000 units at $187.92) (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    1/23/26 7:00:04 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Financials

    Live finance-specific insights

    View All

    Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcas

    1/27/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer's disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the t

    11/3/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presenta

    10/7/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    View All

    Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    11/28/23 6:51:20 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

    10/11/23 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 3:46:49 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 7:26:39 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/13/24 4:58:57 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care